Matt. you, Thank
completion EksoNR most This use business importance home unit, with involving is officially acquisition for are announcing care usual demand is offering of financial The of date, in understated, of be transaction our the this continuum as or also product Human pleased XXXX XXXX to Control closed community and than have QX business continued from as HMC, Hannifin. it & we acquisition across and the typical We're later of and markets. Parker often cannot our to expands Motion our solid weeks why combinations. significant to the results matters
touch this it what in means shortly, I'll to our first, value of bringing detail and our more and the fourth performance. are deal business on patients. we including quarter a business for customers summary But
weeks close We that Indego devices, our generated to EksoHealth million leverage were revenue programs exoskeleton acquisition. of the and of we segment, the to two of current on Throughout EksoHealth continue in our recovery their patients rehabilitative help bookings fourth $X.X were which care. better totaling devices with quarter, the post road in outcomes than health, robotic of which technology standard of improved December, last advanced few booked to included and the XX
revenue In the of internationally. record successfully volume of commercial within year of solid drive on substantial bookings many completion XXXX, and contributed globally and to for we which executed of orders, a both placement our multi-unit strategy, the EksoNR network resulting devices in operators additional
more XXXX. our flow device receiving EksoNR for the MS, to this to for up known first EksoNR in for XX% Demand With continues designation revenue sclerosis segment FDA grow. use EksoHealth from enthusiasm patients than exoskeletal robust to clearance in the suffering compared indication, EksoNR in multiple rehabilitative order remained with by carry for
EksoHealth bookings. the recorded device year, XXX for we Overall,
subscription revenue under and cumulative of our contracted rate Our model. XX%, $X.X conversion have is renewal now than unrecognized more and million we
in neurological their to of made Furthermore, as standard we of many significant rehabilitation. care year, extremity lower with have throughout continue make the large network operators inroads the IDNs or EksoNR they
quarters. Nevertheless, is Our challenging to economic growth the timeline in bullish market our and remain sales taking more pipeline due we conditions, previous although on strong; of new prospects. longer opportunities future remains than
Our integrated to position in believe a commercial overall what sales heading putting favorable us our and are we on be strategy, executing into teams marketing XXXX.
APAC On excited the performance increase international we'll front, by we XX% with in and ongoing growing APAC, in growth regions. in continue this international We're these year-over-year. to than more annual record achieved and our revenue to Europe invest support footprint
to their the Personal. in Indego weakness products expands devices our broadens which Now, with Therapy our in paralysis turning exoskeletons, FDA Ekso use. These into Hannifin, HMC acquisition product business are health extremities. or Indego lower-limb acquired task-specific to Personal, synergistic Parker and Indego and from enable Therapy over-ground is Indego and powered reach patients cleared portfolio our Both home now and of which include: lower training renamed Ekso commercial gait
off most Ekso lightweight exoskeleton home in only for for them modular community exoskeleton, and a device and quick known and and design, individuals in a take which without assistance. is for again, the walk and granting the home users It's Indego at offer of allows level the put use new to connect allows on independence safer to stand to gait portability This community. device a impaired environments. Personal
primarily through more reimbursement but programs veterans been both also funded has opportunities using Veterans rehabilitation internationally. existing through Workmen's the believe there domestically are and traditional is future by to international expand and Indego We and Association, Ekso sold Personal programs. Compensation reimbursement to to programs various supported
to also providing for exoskeleton high Ekso further Indego fitted sessions cord dose adjustable Therapy the primarily that in for facilities. product therapy be outpatient minutes, used can injury, but patients an complementing Ekso's spinal rehabilitation. most in stroke, patients enhance with potential It modular is offering
the Physical at electrical stimulation, premarket month, and new FES, Therapy. for of with notification the FES XXX(k) and showcased Ekso our added software Last U.S. patient integrated hardware and recently we Therapy meeting, to strength. Ekso benefits Administration Drug Food This the with brings muscle filed Indego American covers and further Therapy Association functional Indego improved technology balance forth function, that addition limb allowing or
KAFO, designed in enhance the designed capabilities the and channel looking orthotic established and development models. or orthotics, technology is knee-ankle-foot accessible This industry-leading existing to use of front. standard Ekso is Through O&P, continued the this for or is intelligent of ongoing improve assisted of the payment and robotic industry. market This along reimbursement, added Ekso large care. acquisition, development to prosthetic, products a to this with being technology potential forward
products, sales combination comprised with and these team current highly-experienced former expands the HMC, engineering, along to current of this future and primarily of Ekso Also, include operations, the clinical professionals. employees
research new commercial has decade-long yielded with continued Finally, research with added is collaboration path through this the and relationships The a acquisition, future successful development Ekso's including team, With University. elite experienced to and line quality strategic engineering forces development. core to Vanderbilt Indego this help Ekso innovations. with product to operations partnership of prospects development. and and has expected has provide Vanderbilt staff partner are This for for thrilled key we product and future partners, joined product power academic promised have
line, the a Personal. value our To Ekso to tumors. newly integrated evaluation numerous of patient opted Indego. program Eventually, product of after devices, and participate spinal with exoskeleton [Phil] Despite in explored an his the initially down. seven for recurred I'd a share from like cervical different diagnosed he (ph) tumors through XX to mobility. vertebrae years program, treatments, benefits in therapies of who effort paralyzed to he maintain where a Ekso leaving him utilizing exposure VA's story times, partially mobility of devices increased was Indego ependymoma regained showcase rehabilitation Phil chosen the use four the multiple and neuropathy, was Over to exoskeleton
The Ekso Indego device his aspects helps of countless with Phil daily life.
sports has are digestive he physical physical when processes longer much improved. me are lives our sharing very his given to I would standing our and grateful his challenges experiences Indego confidence and first-hand, For social and Phil, have events exoskeleton honored "Beyond try previously." the see We to the the severe Phil that to improving no products story. According to patients example, not the improvements, of are for
business the segment, industrial offerings approach our construction its customers. to and rescaling In aerospace, product on market remain EksoWorks. resources, strategic to market refocused We marketing EksoWorks the update renewable targets of level commercial refining across and an refocusing manufacturing, automotive, engagement to our temporarily XXXX, go strategies, high-volume with and sales verticals. and while encouraged larger and our our by energy our customers high Turning
to industry these set to to motion into upon strategies with in in and XXXX, As look partners. continue of expand potential progress we the engage execution XXXX we
provide the Now, I'll Jason on that initiatives call himself to turn the an Jason? of over our to background and to overview working Officer, improve Chief on new Jones, efficiencies. be Operating our he'll
